Inventiva Reports Preliminary FY2025 Results, Secures Cash Runway to Q1 2027
Summary
Inventiva S.A. announced preliminary unaudited financial results for fiscal year 2025, reporting €230.9 million in total liquidity and an extended cash runway until the middle of the first quarter of 2027, primarily due to significant capital raises.
Key Events
-
Preliminary FY2025 Financials Released
Inventiva reported preliminary unaudited financial results for the full year ending December 31, 2025.
-
Strong Liquidity Position
Cash and cash equivalents stood at €99.3 million, with an additional €131.6 million in short-term deposits, totaling €230.9 million in liquidity as of December 31, 2025.
-
Extended Cash Runway
The company estimates its current liquidity will finance operations until the middle of the first quarter of 2027.
-
Significant Capital Raises in 2025
Financing activities generated €241.1 million in 2025, including $172.5 million gross from a U.S. public offering and €115.6 million gross from a structured financing tranche.
Analysis
Inventiva S.A. announced preliminary unaudited financial results for fiscal year 2025, highlighting a robust liquidity position and an extended cash runway. The company reported total liquidity of €230.9 million as of December 31, 2025, comprising €99.3 million in cash and cash equivalents and €131.6 million in short-term deposits. This strong financial standing, primarily driven by significant capital raises in 2025, including a $172.5 million public offering and €115.6 million from structured financing, is expected to fund operations until the middle of the first quarter of 2027. While net cash used in operating activities increased to (€104.6) million in 2025 and revenues declined, the successful extension of the cash runway is a critical positive for a clinical-stage biopharmaceutical company, providing stability for its ongoing MASH clinical trials.
At the time of this filing, IVA was trading at $6.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.30 to $7.98. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.